SCHEMBL1035161

SCHEMBL1035161

CC#Cc1cc(C=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALOX12 P18054 1/20 0.43
ADRA1A P35348 1/20 0.43
TK1 P04183 3/20 0.43
TK2 O00142 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ADRB1 P08588 1/20 0.41
DNMT1 P26358 1/20 0.41
PIM1 P11309 1/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CSNK2A3 Q8NEV1 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12768231 1.00 LMNA (0.43) LMNASMN1; SMN2ALOX12ADRA1ATK1
SCHEMBL12768232 0.91 TK1 (0.36) LMNASMN1; SMN2ALOX12ADRA1ATK1
SCHEMBL12697415 0.82 TK1 (0.47) LMNASMN1; SMN2ALOX12ADRA1ATK1
SCHEMBL1032736 0.81 TYMP (0.48)
SCHEMBL2498542 0.80 TK1 (0.42) LMNASMN1; SMN2ALOX12ADRA1ATK1
SCHEMBL24653132 0.80 TK1 (0.53) LMNASMN1; SMN2ALOX12ADRA1ATK1
SCHEMBL2495634 0.79 SLC5A2 (0.42) LMNATK2BLMPMP22DNMT1
SCHEMBL12212659 0.79 SLC5A2 (0.42) LMNATK2BLMPMP22DNMT1
SCHEMBL12212880 0.78 TK1 (0.44) LMNASMN1; SMN2ALOX12ADRA1ATK1
SCHEMBL10340460 0.77 ADRB1 (0.51) LMNASMN1; SMN2ALOX12ADRA1ATK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275538-B1 NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY TAGCYX BIOTECHNOLOGIES (JP) 2016-10-05 EP disclosed
US-8426569-B2 DNA capable of being amplified by PCR with high selectivity and high efficiency RIKEN (JP) 2013-04-23 US disclosed
US-20110053782-A1 NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY RIKEN (JP) 2011-03-03 US disclosed
EP-2275538-A1 NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY Riken (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053782-A1 NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY POLRMT, POLN, POLL LMNA 1568/4885SMN1; SMN2 3594/4885ALOX12 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.